Industries > Pharma > Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Atypical Antipsychotics, Tricyclic Antidepressants (TCAs), Serotonin Antagonist and Reuptake Inhibitors (SARIs), Benzodiazepines; Monoamine Oxidase Inhibitors (MAOIs), Major Depressive Disorder (MDD), General Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive Compulsive Disorder (OCD), Others

PUBLISHED: 29 March 2019
PAGES: 213
PRODUCT CODE: PHA0381
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0381 Categories: , Tags: , , ,

The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 213-page report you will receive 73 tables and 92 figures– all unavailable elsewhere.

The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029

• Our investigation shows forecasts to 2029 for the following submarket by drug class:
• Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Atypical Antipsychotics
• Tricyclic Antidepressants (TCAs)
• Serotonin Antagonist and Reuptake Inhibitors (SARIs)
• Benzodiazepines
• Monoamine Oxidase Inhibitors (MAOIs)
• Others

• Our investigation shows forecasts to 2029 for the following submarket by indication:
• Major Depressive Disorder (MDD)
• General Anxiety Disorder (GAD)
• Panic Disorder (PD)
• Obsessive Compulsive Disorder (OCD)
• Others

• Our investigation shows forecasts to 2029 for the selected leading drugs:
• Abilify
• Abilify Maintena
• Brintellix/Trintellix
• Cipralex/Lexapro
• Cymbalta
• Invega Sustenna/ Xeplion/Trinza/Trevicta
• Lamictal
• Rexulti
• Risperdal Consta
• Zyprexa

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: the US, Canada
• Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
• Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
• RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW

• This report also provides discussion and qualitative analysis on:
• Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
• Antidepressant drugs pipeline analysis
• Anti-anxiety drugs pipeline analysis

• This report discusses the selected leading companies:
• Allergan plc.
• AstraZeneca plc.
• Eli Lilly and Company
• GlaxoSmithKline plc.
• H. Lundbeck A/S
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd.
• Valeant Pharmaceuticals

• Key Questions Answered:
• This report provides in-depth analysis of the antidepressant and anti-anxiety drugs market, identifying the latest trends and forecasting its growth and development over the coming 10 years.
• The study addresses scope of the market in 2018 and assesses commercial drivers and restraints.
• Through reading this report you will gain revenue forecasts from 2018 to 2029 for the overall world market and its leading submarkets, as well as regional and national markets.
• This report provides revenue forecast for the leading antidepressant and anti-anxiety drugs from 2018 to 2019
• Identify drug development trends that will affect market participants from 2018 to 2029.
• See discussions of companies developing, manufacturing, and marketing antidepressant and ant-anxiety drugs, exploring products, technologies, R&D, partnerships, M&A and outlooks.

Visiongain’s study is intended for anyone requiring commercial analyses for the antidepressant and anti-anxiety drugs market. You find data, trends and predictions.

Buy our report today: Global Antidepressant and Anti-anxiety Drugs Market 2019-2029: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Atypical Antipsychotics, Tricyclic Antidepressants (TCAs), Serotonin Antagonist and Reuptake Inhibitors (SARIs), Benzodiazepines; Monoamine Oxidase Inhibitors (MAOIs), Major Depressive Disorder (MDD), General Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive Compulsive Disorder (OCD), Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029


Latest Pharma news

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

READ

Categories

Category